M 40419

Drug Profile

M 40419

Alternative Names: M40419

Latest Information Update: 27 May 2008

Price : $50

At a glance

  • Originator MetaPhore Pharmaceuticals
  • Class Analgesics; Small molecules
  • Mechanism of Action Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 02 Apr 2008 ActivBiotics sells its intellectual property assets including drug product candidates
  • 18 Dec 2007 Suspended - Phase-I for Pain in USA (unspecified route)
  • 18 Dec 2007 M 40419 is available for purchase
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top